Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Cardiac Output Response to Exercise in Relation to Metabolic Demand in Heart Failure with Preserved Ejection Fraction
Abudiab, Muaz M. , Redfield, Margaret M. , Melenovský, Vojtěch , Olson, Thomas P. , Johnson, Bruce D. , Kass, David A. , Borlaug, Barry A. , Melenovský, Vojtěch

European Journal of Heart Failure | February 21, 2013 | Volume: 15 | Issue: 7 | Pages: 776-785

10.1093/eurjhf/hft026 | PMID 23426022 Get It

Abstract Aims Exercise intolerance is a hallmark of heart failure with preserved ejection fraction (HFpEF), yet its mechanisms remain unclear. The current study sought to determine whether increases in cardiac output (CO) during exercise are appropriately matched to metabolic demands in HFpEF. Methods and results Patients with HFpEF (n = 109) and controls (n = 73) exercised to volitional fatigue with simultaneous invasive (n = 96) or non-invasive (n = 86) haemodynamic assessment and expired gas analysis to determine oxygen consumption (VO2) during upright or supine exercise. At rest, HFpEF patients had higher LV filling pressures but similar heart rate, stroke volume, EF, and CO. During supine and upright exercise, HFpEF patients displayed lower peak VO2 coupled with blunted increases in heart rate, stroke volume, EF, and CO compared with controls. LV filling pressures increased dramatically in HFpEF patients, with secondary elevation in pulmonary artery pressures. Reduced peak VO2 in HFpEF patients was predominantly attributable to CO limitation, as the slope of the increase in CO relative to VO2 was 20% lower in HFpEF patients (5.9 ± 2.5 vs. 7.4 ± 2.6 L blood/L O2, P = 0.0005). While absolute increases in arterial–venous O2 difference with exercise were similar in HFpEF patients and controls, augmentation in arterial–venous O2 difference relative to VO2 was greater in HFpEF patients (8.9 ± 3.4 vs. 5.5 ± 2.0 min/dL, P < 0.0001). These differences were observed in the total cohort and when upright and supine exercise modalities were examined individually. Conclusion While diastolic dysfunction promotes congestion and pulmonary hypertension with stress in HFpEF, reduction in exercise capacity is predominantly related to inadequate CO relative to metabolic needs.
Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study
Valerio-Rojas, Juan Carlos , Jaffer, Insara J., Kor, Daryl J. , Cartin‐Ceba, Rodrigo , Gajic, Ognjen

Critical Care Research and Practice | February 20, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-9

10.1155/2013/782573 | PMID 23509620 Get It

Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet therapy could improve the outcomes of septic patients.Methods. We performed a retrospective cohort study of severe sepsis or septic shock adult patients. Outcomes of patients on antiplatelet therapy were compared to those that were not taking antiplatelet therapy by univariate analysis followed by a propensity score analysis based on the probability of receiving antiplatelet therapy.Results. Of 651 patients included in the study 272 (42.8%) were on antiplatelet therapy before the development of severe sepsis or septic shock. After adjusting for important confounding variables antiplatelet therapy was not associated with a decreased risk of hospital mortality (odds ratio 0.73, 95% confidence interval 0.46–1.16). Antiplatelet therapy was associated with a decreased incidence of acute respiratory distress syndrome/acute lung injury (odds ratio 0.50, 95% confidence interval 0.35–0.71) and reduced need of mechanical ventilation (odds ratio 0.62, 95% confidence interval 0.45–87). Incidence of acute kidney injury was similar between both groups (odds ratio 1.08, 95% confidence interval 0.73–1.59).Conclusions. The use of antiplatelet therapy before the diagnosis of severe sepsis or septic shock was not associated with decreased hospital mortality. Antiplatelet therapy was associated with a decreased incidence of acute lung injury/acute respiratory distress syndrome.
Postoperative Supplemental Oxygen and High Intraoperative Inspired Oxygen
Nemergut, Michael E. , Räsänen, Jukka, Downs, John B.

Anesthesiology | February 20, 2013 | Volume: 118 | Issue: 3 | Pages: 756-756

10.1097/aln.0b013e3182815ace | PMID 23426215 Get It

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Catalano, John, Deininger, Michael W. , Shields, Alan L. , Miller, Carole B., Silver, Richard T. , Talpaz, Moshe , Winton, Elliott F., Harvey, Jimmie H., Hare, Thomas, Erickson‐Viitanen, Susan, Sandor, Victor, Levy, Richard S., Kantarjian, Hagop M. , Verstovšek, Srđan , Mesa, Ruben A. , Gotlib, Jason , Gupta, Vikas , Sun, William , Verstovsek, Srdan , Talpaz, Moshe , Kantarjian, Hagop

Journal of Clinical Oncology | February 20, 2013 | Volume: 31 | Issue: 10 | Pages: 1285-1292

10.1200/jco.2012.44.4489 | PMID 23423753 Get It

Purpose To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis. Patients and Methods COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment–I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis. Exploratory analyses were conducted on the following patient-reported outcomes (PROs) assessments: modified MFSAF v2.0 (individual symptoms and Total Symptom Score [TSS]), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and Patient Global Impression of Change (PGIC). Results Patients receiving ruxolitinib experienced improvements in individual myelofibrosis-related symptoms, although patients receiving placebo experienced worsening (P < .001). The majority (91%) of ruxolitinib-treated patients designated as ≥ 50% TSS responders (≥ 50% TSS improvement) self-reported their condition as either “Much improved” or “Very much improved” on the PGIC. These patients achieved significant improvements in the EORTC QLQ-C30 functional domains and Global Health Status/QoL versus patients receiving placebo, who experienced worsening on these measures (P ≤ .0135). Ruxolitinib-treated patients with a lesser degree of symptom improvement (< 50% TSS responders) also achieved improvements over placebo on these measures. The degree of spleen volume reduction with ruxolitinib correlated with improvements in TSS, PGIC, PROMIS Fatigue Scale, and EORTC Global Health Status/QoL. Ruxolitinib-treated patients who achieved a ≥ 35% reduction in spleen volume experienced the greatest improvements in these PROs. Conclusion Ruxolitinib-treated patients achieved clinically meaningful improvements in myelofibrosis-related symptoms and QoL, but patients receiving placebo reported worsening of symptoms and other PROs.
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach
Baker, Angela , Braggio, Esteban , Jacobus, Susanna , Jung, Sungwon , Therneau, Terry M. , Dispenzieri, Angela , Wier, Scott A. Van, Ahmann, Gregory , Levy, Joan, Perkins, Louise M. , Kim, Seungchan , Henderson, Kimberly J., Vesole, David H., Rajkumar, S. Vincent , Jelinek, Diane F., Carpten, John D. , Fonseca, Rafaël , Larson, Dirk R. , Rajkumar, S Vincent , Dispenzieri, Angela , Braggio, Esteban , Fonseca, Rafael

Blood | February 20, 2013 | Volume: 121 | Issue: 16 | Pages: 3147-3152

10.1182/blood-2012-07-443606 | PMID 23422747 Get It

Key PointsIn this study, African American MM patients have a significantly lower frequency of IgH translocations than European American patients.
Toward Quality Care in ADHD
Rostain, Anthony L., Miesle, Laura M., Jensen, Peter S. , Connor, Daniel F. , Faraone, Stephen V.

Journal of Attention Disorders | February 20, 2013 | Volume: 19 | Issue: 2 | Pages: 99-117

10.1177/1087054712473835 | PMID 23422237 Get It

Objective: Therapeutic goals for chronic mental disorders like major depressive disorder (MDD) and schizophrenia have evolved in parallel with the growing medical knowledge about the course and treatment of these disorders. Although the knowledge base regarding the clinical course of ADHD, a chronic psychiatric disorder, has evolved beyond symptomatic improvement and short-term treatment response, long-term goals, such as functional remission, have not yet been clearly defined. Method: A PubMed literature search was conducted to investigate the therapeutic goals of pharmacologic treatment referenced in the published literature from January 1998 through February 2010 using the following commonly used ADHD treatments as keywords: amphetamine, methylphenidate, atomoxetine, lisdexamfetamine, guanfacine, and clonidine. This search was then combined with an additional search that included the following outcome keywords: remission, relapse, remit, response, normal, normalization, recovery, and effectiveness. Results: Our search identified 102 publications. The majority (88.2% [90/102]) of these contained predefined criteria for treatment response. Predefined criteria for normalization and remission and/or relapse were presented in 4.9% (5/102), 12.7% (13/102), and 3.9% (4/102) of publications, respectively. There was a lack of consistency between the instruments used to measure outcomes as well as the criteria used to define treatment response, normalization, and remission as well as relapse. Conclusion: The therapeutic goals in treating ADHD should address optimal treatment outcomes that go beyond modest reductions of ADHD symptoms to include syndromatic, symptomatic, and functional remission. Future work should focus on reliable and valid tools to measure these outcomes in the clinical trial setting.
In Mildly Symptomatic Patients, Should an Invasive Strategy with Catheterization and Revascularization Be Routinely Undertaken?
Ting, Henry H. , Maron, David J.

Circulation: Cardiovascular Interventions | February 19, 2013 | Volume: 6 | Issue: 1 | Pages: 114-121

10.1161/circinterventions.112.973438 | PMID 23424271 Get It

Substrate-Guided Proteomics Enhances Degradome Resolution
Arrell, D. Kent , Terzic, André

Circulation: Cardiovascular Genetics | February 19, 2013 | Volume: 6 | Issue: 1 | Pages: 7-9

10.1161/circgenetics.111.000031 | PMID 23424255 Get It

Adapting Lymphedema Treatment to the Palliative Setting
Andrews, Karen L., Kollasch, Jenny, Schmidt, Kenley D., Basford, Jeffrey, Cheville, Andrea

American Journal of Hospice and Palliative Medicine® | February 19, 2013 | Volume: 31 | Issue: 1 | Pages: 38-44

10.1177/1049909112475297 | PMID 23423772 Get It

Objective: To review the benefits of adapting the complex techniques of formal lymphedema therapy to the more generalized forms of edema often seen in the chronic disease and palliative care settings. Data Sources: Peer-reviewed literature and clinical practice. Conclusion: Lymphedema treatment modalities have much to offer beyond their well-characterized benefit in classical lymphedema. In modified forms, they may improve and lessen the burden of refractory edema originating from a diverse range of causes. Thoughtful planning and practice, however, are essential as an inadequate adaptation may result in unnecessary effort, injury for the patient, or an unsatisfactory outcome.